Shareholders Equity: The sum of preferred and common equity items.
Gyre Therapeutics, Inc. (GYRE) had Shareholders Equity of $129.44M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
$26.77M |
|
$0.44M |
|
$4.58M |
|
$22.20M |
|
$24.60M |
|
$2.17M |
|
$0.07M |
|
$2.24M |
|
$2.24M |
|
$1.58M |
|
$1.58M |
|
$1.58M |
|
$1.58M |
|
$2.17M |
|
$2.81M |
|
89.12M |
|
102.70M |
|
$0.00 |
|
$0.00 |
|
| Balance Sheet Financials | |
$91.28M |
|
$23.40M |
|
$61.36M |
|
$152.65M |
|
$16.92M |
|
-- |
|
$6.28M |
|
$23.20M |
|
$129.44M |
|
$124.48M |
|
|
Shareholders Equity |
$129.44M |
90.82M |
|
| Cash Flow Statement Financials | |
$1.96M |
|
$-1.07M |
|
$23.70M |
|
$11.81M |
|
$36.49M |
|
$24.68M |
|
$1.41M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.40 |
|
-- |
|
-- |
|
-- |
|
-- |
|
82.91% |
|
8.11% |
|
8.11% |
|
-- |
|
8.36% |
|
1.65% |
|
$1.60M |
|
-- |
|
-- |
|
-- |
|
0.18 |
|
0.52 |
|
1.08 |
|
83.57 |
|
1.22% |
|
1.27% |
|
1.03% |
|
1.22% |
|
$1.43 |
|
$0.02 |
|
$0.02 |
|